% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Penack:286992,
      author       = {O. Penack and T. Luft and C. Peczynski and A. Benner$^*$
                      and S. Sica and M. Arat and M. Itäla-Remes and L. L. Corral
                      and N. P. M. Schaap and M. Karas and L. Raida and T.
                      Schroeder and P. Dreger and E. Metafuni and T. Ozcelik and
                      B. M. Sandmaier and L. Kordelas and I. Moiseev and H.
                      Schoemans and C. Koenecke and G. W. Basak and Z. Peric},
      title        = {{E}ndothelial {A}ctivation and {S}tress {I}ndex ({EASIX})
                      to predict mortality after allogeneic stem cell
                      transplantation: a prospective study.},
      journal      = {Journal for ImmunoTherapy of Cancer},
      volume       = {12},
      number       = {1},
      issn         = {2051-1426},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2024-00109},
      pages        = {e007635},
      year         = {2024},
      abstract     = {We previously reported that the 'Endothelial Activation and
                      Stress Index' (EASIX; ((creatinine×lactate
                      dehydrogenase)÷thrombocytes)) measured before start of
                      conditioning predicts mortality after allogeneic
                      hematopoietic stem cell transplantation (alloSCT) when used
                      as continuous score. For broad clinical implementation, a
                      prospectively validated EASIX-pre cut-off is needed that
                      defines a high-risk cohort and is easy to use.In the current
                      study, we first performed a retrospective cohort analysis in
                      n=2022 alloSCT recipients and identified an optimal cut-off
                      for predicting non-relapse mortality (NRM) as EASIX-pre=3.
                      For cut-off validation, we conducted a multicenter
                      prospective study with inclusion of n=317 first alloSCTs
                      from peripheral blood stem cell in adult patients with acute
                      leukemia, lymphoma or myelodysplastic
                      syndrome/myeloproliferative neoplasms in the European
                      Society for Blood and Marrow Transplantation
                      network.Twenty-three $\%$ (n=74) of alloSCT recipients had
                      EASIX-pre ≥3 taken before conditioning. NRM at 2 years was
                      $31.1\%$ in the high EASIX group versus $11.5\%$ in the low
                      EASIX group (p<0.001). Patients with high EASIX-pre also had
                      worse 2 years overall survival $(51.6\%$ vs $70.9\%;$
                      p=0.002). We were able to validate the cut-off and found
                      that EASIX ≥3 was associated with more than twofold
                      increased risk for NRM in multivariate analysis (HR=2.18,
                      $95\%$ CI 1.2 to 3.94; p=0.01). No statistically significant
                      difference could be observed for the incidence of
                      relapse.The results of this study provide a prospectively
                      validated standard laboratory biomarker index to estimate
                      the transplant-related mortality risk after alloSCT. EASIX
                      ≥3 taken before conditioning identifies a population of
                      alloSCT recipients who have a more than twofold increased
                      risk of treatment-related mortality.},
      keywords     = {Hematologic Neoplasms (Other) / Immunotherapy (Other) /
                      Inflammation (Other)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38199608},
      doi          = {10.1136/jitc-2023-007635},
      url          = {https://inrepo02.dkfz.de/record/286992},
}